ZEVRA THERAPEUTICS, INC. ZVRA

Rank #2491 · Nasdaq · $0.6B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

13.6

P/E

-5.8

P/B

9.82

ROE

-170.6%

Op. Margin

-368.5%

Debt Ratio

224%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -5.8x, P/B 9.82x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -170.6%. Ranks in the top 96% of the universe.

Safety ★★☆☆☆

Weak

Debt ratio 224%. Ranks in the top 65% of the universe. Above 200% signals meaningful leverage risk.

Growth ★☆☆☆☆

Poor

Revenue decline of 14.0% year over year. Ranks in the top 87% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	–	$-0.0B	$-0.0B	$-0.0B	–	-198
2016	–	$-0.0B	$-0.0B	$-0.0B	–	-267
2017	–	$-0.0B	$-0.1B	$-0.0B	–	-214
2018	–	$-0.0B	$-0.0B	$-0.0B	–	-588
2019	$0.0B	$-0.1B	$-0.1B	$-0.1B	–	-162
2020	$0.0B	$-0.0B	$-0.0B	$-0.1B	-158.4	-128
2021	$0.0B	$-0.0B	$-0.0B	$-0.1B	-42.2	-104
2022	$0.0B	$0.0B	$-0.0B	$-0.1B	27.0	-9
2023	$0.0B	$-0.0B	$-0.0B	$0.1B	-418.9	40
2024	$0.0B	$-0.0B	$-0.0B	$0.1B	-180.6	147
2025	$0.0B	$-0.1B	$-0.1B	$0.1B	-368.5	224